Physician profile
Tova Kosowsky
NPI 1649831694
$845.25
in general payments reported to CMS, 2019-2025
9 companies · $620 in 2025
The $620 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $42.66 · 2024: $183 · 2025: $620.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $803.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $802.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $233.68 | 2022-2025 | Idosetr |
| Abbvie INC. | $197.94 | 2025 | |
| Rxsight INC | $101.98 | 2024 | Rxsight Injector Cartridge, Light Adjustable Lens (Lal), Rxsight Contact Lens |
| Bausch & Lomb Americas INC. | $67.47 | 2024-2025 | Miebo, Xiidra, Vyzulta |
| Oyster Point Pharma, INC. | $63.96 | 2025 | Ryzumvi, Tyrvaya |
| Alcon Vision LLC | $60.00 | 2024 | Lensx |
| Tarsus Pharmaceuticals, INC. | $54.76 | 2025 | Xdemvy |
| Amgen INC. | $44.99 | 2025 | Tepezza |
| Carl Zeiss Meditec Cataract Technology INC. | $20.47 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tova Kosowsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.